Please assess the completion status of the following clinical trial:

Trial Title: HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than 18 years old woman,~* Documented HIV-1 seropositive,~* CD4 count greater than 200,~* Not on HIV antiretroviral therapy,~* HSV-2 seropositive as determined by Focus EIA (IN \>3.5)~* Not intending to move out of the area for the duration of study participation.~* Willing and able to:provide independent written informed consent;undergo clinical evaluations;take study drug as directed;adhere to follow-up schedule.~* Bacterial STDs (symptomatic STD syndromes or laboratory-confirmed asymptomatic gonorrhea and syphilis) are treated within two weeks of study enrollment and random assignment.~Exclusion Criteria:~Women who meet any of the following criteria are not eligible for this study:~* Known history of adverse reaction to valacyclovir, acyclovir or famciclovir;~* Planned open label use of acyclovir, valacyclovir, or famciclovir~* Known medical history of seizures~* Known renal failure, serum creatinine \>2.0mg/dl~* Hematocrit \< 30 %

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).